Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theriva Biologics, Inc. (TOVX) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Theriva’s clinical-stage programs, capital structure, and corporate actions, complementing its press releases and scientific presentations.
Investors can review Form 10-K and Form 10-Q annual and quarterly reports for discussions of risk factors, research and development activities, and financial condition related to programs such as VCN-01, SYN-004 (ribaxamase), SYN-020, and the VCN-X discovery efforts. Current reports on Form 8-K describe material events, including clinical data announcements, regulatory feedback from agencies such as the European Medicines Agency, warrant inducement agreements, public offerings, and at-the-market sales agreements.
Theriva’s proxy statements on Schedule 14A outline matters submitted to stockholders, such as proposals to approve the issuance of additional common shares upon exercise of warrants issued in private placements. These documents explain voting mechanics, record dates, and the rationale for share authorization requests tied to financing transactions.
Forms related to securities offerings, such as registration statements and prospectus supplements referenced in 8-K filings, describe the terms of public offerings of common stock and warrants, as well as at-the-market programs through placement agents. Together, these filings help clarify how Theriva funds the development of its clinical pipeline.
On this page, Stock Titan pairs Theriva’s SEC filings with AI-powered summaries that highlight key points, such as changes in capital structure, new clinical or regulatory disclosures, and important risk factor updates. Real-time updates from EDGAR, along with structured access to historical filings, allow users to monitor how Theriva’s regulatory and financing profile evolves alongside its investigational therapies.
Theriva Biologics (TOVX) launched an at‑the‑market (ATM) offering of up to $4,019,597 of common stock under a prospectus supplement to its effective S‑3 shelf. Sales will be made through A.G.P./Alliance Global Partners as sales agent, which will earn a commission of up to 3.0% of the gross sales price per share.
The filing is made pursuant to General Instruction I.B.6 to Form S‑3, which limits primary sales to one‑third of public float; the company reports a public float of approximately $19,659,047 based on 23,403,628 non‑affiliate shares at $0.84 as of October 15, 2025. The company notes it sold approximately 12,016,073 shares for net proceeds of about $6.1 million through the Sales Agreement during the period ended December 31, 2024 through the date of the supplement.
For illustration, the company shows up to 13,407,595 shares at an offering price of $0.2998 (the October 21, 2025 last sale price), with actual shares varying by market price. Intended uses include working capital and general corporate purposes, including research and development and manufacturing scale‑up.
Empery Asset Management and two managing members filed an amended Schedule 13G reporting beneficial ownership of 504,091 shares of Theriva Biologics (TOVX), equal to 4.99% of the class. The reported shares are issuable upon exercise of warrants and are subject to a 4.99% Beneficial Ownership Limitation (the “Blocker”).
The filers report shared voting and dispositive power over 504,091 shares and no sole power. The ownership percentage is calculated using 9,597,952 shares outstanding as of August 7, 2025, as disclosed in the company’s Form 10‑Q. The filing certifies the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
Theriva Biologics (TOVX) filed a Form 8-K announcing new clinical data visibility. On October 20, 2025, the company presented expanded metastatic pancreatic ductal adenocarcinoma (mPDAC) data from its VIRAGE Phase 2b trial (NCT05673811) at the ESMO 2025 Annual Congress. The related ESMO presentation is furnished as Exhibit 99.1 and incorporated by reference.
Theriva Biologics (TOVX) entered a warrant inducement agreement leading certain holders to exercise 8,092,280 existing warrants at $0.54 per share. The company received approximately $4.4 million in gross proceeds on the October 17, 2025 closing.
In return, Theriva issued 16,184,560 new common stock purchase warrants at $0.54, which become exercisable only after Stockholder Approval and NYSE American approval, and expire five years from that approval date. The new warrants and underlying shares were issued in a private placement under Section 4(a)(2) and Rule 506(b). The company will file a resale registration statement as soon as practicable and seek effectiveness within stated SEC review timelines.
Terms include beneficial ownership caps of 4.99% (or 9.99% upon election), a 45‑day restriction on new issuances/registrations (with exceptions), and a 90‑day prohibition on Variable Rate Transactions, with ATM sales permitted five days after closing. Net proceeds are earmarked for working capital. AGP advised and earns a 7.0% cash fee on gross proceeds plus expenses.
Theriva Biologics (TOVX) amended certain existing warrants, reducing the exercise price from $2.00 to $0.54 per share for warrants held by certain holders covering up to 1,345,000 shares of common stock. The change was executed on October 16, 2025 and disclosed via this amendment to a prior prospectus supplement tied to the company’s effective S-1.
The filing updates the earlier prospectus to reflect the revised pricing terms for these “Existing Warrants.” This adjustment affects only the warrant exercise price mechanics and does not alter the previously described securities from the earlier offering materials. Theriva’s common stock closed at $0.84 on October 15, 2025 on the NYSE Capital Market, providing context for the new exercise price.
Theriva Biologics (TOVX) amended certain outstanding warrants, lowering the exercise price from $1.10 to $0.54 per share for warrants to purchase up to 6,747,280 shares of common stock. The change was agreed with the relevant warrant holders on October 16, 2025, and updates the prior prospectus supplement disclosure.
The company’s common stock trades on the NYSE Capital Market under “TOVX.” On October 15, 2025, shares closed at $0.84. This amendment pertains to previously issued warrants tied to a prior best efforts offering; it does not describe a new sale of shares.
Theriva Biologics filed a prospectus supplement disclosing an amendment to certain existing warrants. On October 16, 2025, the company reduced the exercise price on warrants to purchase up to 1,385,000 shares of common stock from $2.00 to $0.54 per share.
This supplement updates the company’s previously effective S-1 prospectus. The change applies only to specified “Existing Warrants” held by certain holders. Theriva’s common stock trades on the NYSE Capital Market under the symbol TOVX, and the closing price was $0.84 per share on October 15, 2025.
Theriva Biologics (TOVX) filed a prospectus supplement to disclose an amendment to certain outstanding common warrants. On October 16, 2025, the company and certain holders agreed to reduce the exercise price on Existing Warrants covering up to 6,727,280 shares of common stock from $1.10 to $0.54 per share. The supplement updates the previously effective S-1 prospectus tied to the May 2025 best efforts offering. Theriva’s common stock closed at $0.84 on October 15, 2025 on the NYSE Capital Market under the symbol TOVX.
Theriva Biologics (TOVX) furnished an update on clinical data to be presented on October 20, 2025 at ESMO 2025 from the VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma. The study compared standard gemcitabine/nab‑paclitaxel (GA; Arm I) to VCN‑01 plus GA (Arm II).
In the full analysis set, median overall survival was 10.8 months for Arm II vs 8.6 months for Arm I (HR 0.57; 95% CI 0.34–0.96; P=0.055). Progression‑free survival was 7.0 vs 4.6 months (HR 0.55; 95% CI 0.34–0.88; P=0.011), and duration of response was 11.2 vs 5.4 months (HR 0.22; 95% CI 0.08–0.62; P=0.004). In a subgroup receiving two doses of VCN‑01 and starting GA cycle 4, overall survival was 14.8 vs 11.6 months (HR 0.44; 95% CI 0.21–0.92; P=0.046), and PFS was 11.2 vs 7.4 months (HR 0.48; 95% CI 0.25–0.91; P=0.017).
The company reports the study met its primary endpoints and VCN‑01 was well tolerated; all VCN‑01‑related serious adverse events (n=13) resolved, with flu‑like symptoms (13.2%), transaminase increases (5.7%), and drug‑induced liver injury (3.8%) most common. A separate poster on previously reported SYN‑004 data will appear at IDWeek 2025.
Theriva Biologics, Inc. reported new preclinical results for its next-generation oncolytic adenovirus VCN-12, developed within the VCN-X discovery program. The data were presented at the 32nd Annual Congress of the European Society of Gene & Cell Therapy and the full presentation is available as Exhibit 99.1.
VCN-12 uses the same capsid as the company’s lead clinical candidate VCN-01 but is engineered to increase stroma degradation by replacing human hyaluronidase PH20 with a more active bee hyaluronidase, and to boost tumor cell lysis by expressing the pore-forming protein parasporin-2. In vitro, VCN-12 showed increased cancer cell killing and higher hyaluronidase activity compared to VCN-01. In animal models, intravenous VCN-12 had a similar toxicity profile to VCN-01, while intratumoral dosing significantly reduced tumor growth versus VCN-01 in immunocompetent hamsters with HP-1 pancreatic tumors.
The antitumor effect was seen in both injected tumors and separate tumors implanted later but not injected. Complete regression of the first tumor occurred in two of nine hamsters, and the second implanted tumors did not grow in these animals. A persistent immune response appeared to prevent new tumor establishment when HP-1 cells were implanted again 43 days after VCN-12 treatment in these responders. The company plans further preclinical studies to expand on these findings.